论文部分内容阅读
医药 医药业走向“巨头时代” 今年第一季度,我国医药行业亏损面大幅增加,持续亏损和由盈转亏的企业上 升到二成以上;但与此同时,销售收入却比去年同期增长10.9％,利润总额同比增长 17.2％。业内人士指出:这表明我国医药工业正处在重新大洗牌中,开始走向“巨头时 代”,行业利润正由分散集中到几大巨头的囊中。预计未来国内也将会出现几大医药 集团垄断的局面,企业并购将是未来发展的主题。
The pharmaceutical and pharmaceutical industry is moving toward a “giant era.” In the first quarter of this year, China’s pharmaceutical industry suffered a substantial increase in its loss. The sustained losses and losses from companies that turned from losses to profits rose to over 20%; at the same time, sales revenue increased by 10.9% over the same period of last year. The total profit increased by 17.2% year-on-year. Insiders pointed out: This shows that China’s pharmaceutical industry is undergoing a major reshuffle, and it has begun to move toward the “giant time”, and the industry’s profits are being scattered and concentrated in the pockets of several giants. It is expected that in the future there will also be a monopoly of several major pharmaceutical groups in China. M&A will be the subject of future development.